



## Immune Response and Immunotherapy in Bladder Cancer

Guest Editors:

**Dr. Alfredo Minguela**

Clinic University Hospital Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120 El Palmar Murcia, Spain

**Dr. Pedro López-Cubillana**

Clinic University Hospital Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120 El Palmar Murcia, Spain

Deadline for manuscript submissions:

**closed (31 March 2022)**

### Message from the Guest Editors

Bladder cancer represents a wide spectrum of diseases, ranging from recurrent noninvasive tumors to those at aggressive or advanced stages that require intensive treatments. Bladder cancer accounts for an estimated 500,000 new cases and 200,000 deaths yearly worldwide. Understanding the underlying biology of bladder cancer has changed how this disease is diagnosed and treated. Bladder cancer is highly immunogenic, involving innate and adaptive components of the immune system. Although little is still known of how immune cells respond to bladder cancer, immunotherapy with the bacille Calmette–Guerin (BCG) remains the gold standard in non-muscle invasive bladder cancer. In addition, the use of immunotherapy to block immune checkpoints (anti-CTLA4 and anti-PD1/PD-L1) used to boost natural immune vigilance is emerging as an effective therapy in invasive and metastatic urologic tumors. This Special Issue aims to unravel the immune responses involving innate and adaptive immune cells in bladder cancer that will contribute to establishing new and promising therapeutic options, while reviewing the immunotherapies currently in use in bladder cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)